Company: LNAI
Filing Date: 2025-03-06
Form Type: 8-K
Source: 0001731122-25-000354
Chunk: 0

Company: Lunai Bioworks Inc.
Filing Date: 2025-03-06
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

As previously reported, on January
1, 2025, Renovaro, Inc., a Delaware corporation (“ Renovaro”), entered into binding letter of intent (the “LOI”)
with Predictive Oncology Inc., a Delaware corporation (“ Predictive Oncology”), with respect to the proposed acquisition
of all of the capital stock of Predictive Oncology by Renovaro (the “ Transaction”). On February 28, 2025, Renovaro
entered into an extension agreement with Predictive Oncology (the “ Extension Agreement”), pursuant to which the parties
amended the LOI to (i) eliminate Renovaro’s obligation to acquire certain shares of Predictive Oncology’s common stock and
(ii) extend the outside termination date of the LOI from February 28, 2025 to March 31, 2025. Additionally, pursuant to the Extension
Agreement, Renovaro acquired 467,290 shares of Predictive Oncology’s common stock for an aggregate purchase price of $500,000 and
agreed to purchase an additional 901,298 shares of Predictive Oncology common stock for an aggregate of $964,389 upon, and subject to,
the execution of a definitive agreement in respect of the Transaction.